Abbott has announced results from the FreeDM2 randomised controlled trial (RCT), indicating that improved glucose outcomes were observed in individuals using the FreeStyle Libre continuous glucose monitoring (CGM) technology for type 2 diabetes (T2D).
The findings were presented at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The FreeDM2 trial aimed to evaluate whether real-time CGM could help people on basal insulin manage their glucose better. It was carried out at 24 clinical sites across the UK and included 303 participants.
This study compared CGM with traditional self-monitoring of blood glucose (SMBG) among people with T2D.
After four months, participants using FreeStyle Libre CGM experienced a notably greater decrease in glycated haemoglobin (HbA1c) compared to those relying on fingerstick testing. They also spent around 2.5 additional hours daily within the target glucose range, representing a 10.4% increase.
The study group included participants taking basal insulin in combination with either a sodium-glucose cotransporter-2 (SGLT2) inhibitor or a glucagon-like peptide-1 (GLP-1) receptor agonist, indicating that these improvements were observed even among those already receiving advanced glucose-lowering treatments.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSeparately, an Italian interventional study presented at ATTD monitored 88 adults with T2D who were using basal insulin and the FreeStyle Libre system.
After three months, participants reported more time in the healthy range, improved average glucose levels, and better quality of life.
Abbott diabetes care’s chief medical officer Mahmood Kazemi said: “Across both studies, real-time glucose visibility gives people the understanding they need to make small, informed adjustments throughout the day.
“In the FreeDM2 study, people made these adjustments on their own. Seeing similar patterns in the Italian study reinforces that the value comes from continuous access to glucose information itself, rather than from any single device feature.”
Earlier this month, Abbott secured the US Food and Drug Administration approval for its next-generation CardioMEMS HERO device, which is designed to support remote heart failure monitoring.
